SCYNEXIS, Inc. is a clinical‐stage biotechnology company dedicated to discovering and developing novel anti‐infective therapies with an initial focus on antifungal treatments. The company’s proprietary platform centers on triterpenoid glucan synthase inhibitors, a mechanism designed to target and disrupt the cell walls of pathogenic fungi. With its lead candidate, ibrexafungerp, SCYNEXIS is pioneering the first approved oral and intravenous agents in a new antifungal class.
Ibrexafungerp (formerly SCY-078) has achieved regulatory approval for the treatment of vulvovaginal candidiasis and is advancing additional indications, including invasive candidiasis and aspergillosis. In parallel, the company is developing rezafungin (CD101), a once‐weekly intravenous echinocandin designed to improve upon existing therapies for serious systemic fungal infections. SCYNEXIS collaborates with contract manufacturing organizations and global clinical research partners to support these programs through pivotal trials and regulatory filings.
Founded in 2009 and headquartered in Research Triangle Park, North Carolina, SCYNEXIS operates a research and development hub focused on antifungal innovation. The company’s development efforts extend across North America, Europe and Asia Pacific, with clinical trial sites in multiple countries and strategic alliances that facilitate manufacturing scale‐up and distribution. Through these partnerships, SCYNEXIS aims to address significant unmet medical needs in immunocompromised patients and those at high risk of fungal infections.
Under the leadership of Paul A. Tcheng, M.D., who serves as President, CEO and Chairman, the company has built a management team with deep expertise in infectious disease drug development, regulatory affairs and commercialization. SCYNEXIS continues to expand its pipeline with next‐generation compounds and anticipates further clinical milestones as it progresses toward broadening patient access to new antifungal therapies.
AI Generated. May Contain Errors.
